Illumina launches dataset to speed up AI-powered drug discovery

, By The Economic Times
Illumina launches dataset to speed up AI-powered drug discovery
AI

Share via:



Gene sequencing company Illumina on Tuesday introduced a ‍dataset that maps genetic changes to help accelerate drug discovery ⁠through artificial intelligence.

The company said it was partnering with drugmakers AstraZeneca, Merck and Eli Lilly for its Billion Cell Atlas, which will ‌train advanced ‌AI models at scale and advance research into fundamental disease mechanisms that have ‌previously been out of reach.

Drug developers are increasingly adopting AI for discovery and safety testing to get faster and cheaper results, in line with the



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Previous News
Apple Introduces Apple Creator Studio, Signaling a Major Shift in How Creators Work Across Apple Devices
Next News
Fleet Management Startup Carrum Secures $7 Mn From Uber
The Economic Times

Popular

More Like this

Load more

Illumina launches dataset to speed up AI-powered drug discovery

, Published By The Economic Times
Illumina launches dataset to speed up AI-powered drug discovery
AI



Gene sequencing company Illumina on Tuesday introduced a ‍dataset that maps genetic changes to help accelerate drug discovery ⁠through artificial intelligence.

The company said it was partnering with drugmakers AstraZeneca, Merck and Eli Lilly for its Billion Cell Atlas, which will ‌train advanced ‌AI models at scale and advance research into fundamental disease mechanisms that have ‌previously been out of reach.

Drug developers are increasingly adopting AI for discovery and safety testing to get faster and cheaper results, in line with the



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

Previous News
Apple Introduces Apple Creator Studio, Signaling a Major Shift in How Creators Work Across Apple Devices
Next News
Fleet Management Startup Carrum Secures $7 Mn From Uber
The Economic Times

More like this

Transmission Line Safety Suit Saves Line Workers’ Lives

Tech IEEE Spectrum -
In 2018, Justin Kropp was restoring a fire-damaged transmission...

Microsoft Pledges to Pay More for Electricity, Drawing Praise...

Tech NYTimes -
The tech giant is responding to concerns that data...

Ingenico Brings Stablecoin Payments to In-Store Checkout

Blockchain Cointelegraph -
Payments terminal provider Ingenico has partnered with WalletConnect...
Load more

Popular

Block title

iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv subscription iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv iptv

Startup Events

Trending News

About

Partnership

Contact us

© 2026 StartupNews.fyi | DOTFYI Media Ventures Private Limited. All Rights Reserved.